In this study, combined with the results of network pharmacology and molecular docking, we speculate that the mechanism of PSP therapy for breast cancers may be related to the promotion of apoptosis and inhibition of tumor growth by targeting JAK2-STAT3 signaling pathway. This evidence concerns the gene JAK2 and breast carcinoma.